Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07485335 · ClinicalTrials.gov registry record · Phase 4
A Bundled Intervention to End Opioid Overdoses
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Not yet
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
NCT07485335: Clinical Trial Phase 4 study, sponsored by University of Alabama at Birmingham.
NCT07485335 is a Phase 4 study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 160 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07485335, a Phase 4 study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
Study Summary
Opioid overdose deaths have reached historically high records in the United States and are particularly concentrated among patients after emergency department (ED) discharge. Evidence-based treatment modules to reduce repeat opioid overdose and mortality are lacking in this patient population. A bundled intervention is proposed, including telehealth, peer support specialist, buprenorphine, and linkage for definitive care, that is designed to increase treatment uptake in this patient population post-ED discharge, reduce repeat opioid overdoses, and end overdose deaths.
Primary Outcome
measure the total number of participants who complete 1- month and 3-month treatment in the study
Interventions
- OTHER control group
- OTHER Bundled intervention (Experimental)
- DRUG Buprenorphine (Experimental)
- BEHAVIORAL Scheduled Peer Support Specialist (Experimental)
- OTHER Telemedicine Buprenorphine Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-09-07 |
| Est. Completion | 2030-09-30 |
| Phase | Phase 4 |
What is known before NCT07485335 opens enrollment
NCT07485335 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 5 interventions - of which control group is the first listed.
NCT07485335 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07485335 about?
NCT07485335 is a clinical study titled "A Bundled Intervention to End Opioid Overdoses". Opioid overdose deaths have reached historically high records in the United States and are particularly concentrated among patients after emergency department (ED) discharge. Evidence-based treatment modules to reduce repeat opioid overdose and mortality are lacking in this patient population. A bun...
What is the current status of trial NCT07485335?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2026-09-07. Estimated completion is 2030-09-30.
What interventions are being tested in trial NCT07485335?
The interventions under investigation include: control group (OTHER), Bundled intervention (Experimental) (OTHER), Buprenorphine (Experimental) (DRUG), Scheduled Peer Support Specialist (Experimental) (BEHAVIORAL), Telemedicine Buprenorphine Treatment (OTHER).
Who is sponsoring clinical trial NCT07485335?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07485335's enrollment target sits among peer trials
160 507th of 2000 higher than 1,485 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI